CD40L-Fc FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
OwnerManuel Baca, Stacey Drabic +2inventors
InventorsMANUEL BACA, STACEY DRABIC, PETER EMTAGE, RONALD HERBST
Life of this patent
Estimating the term…
Abstract
Provided herein is a CD40L-Fc fusion protein and methods of using the fusion protein in the treatment of cancer comprising administering the CD40L-Fc fusion protein or the CD40L-Fc fusion protein in combination with one or more immune checkpoint inhibitors (e.g., an anti-CTLA4 antibody, anti-PD-L1 antibody).
Claims18
1-24. (canceled)
A method of activating a CD40 polypeptide, comprising contacting the CD40 polypeptide with a single chain fusion selected from the group comprising amino acid SEQ ID:
- 9, SEQ ID NO:
- 10, and SEQ ID NO:
- 11 fusion protein.
A method of enhancing an anti-tumor immune response in a subject comprising administering to the subject a single chain fusion selected from the group comprising amino acid SEQ ID:
- 9, SEQ ID NO:
- 10, and SEQ ID NO:
- 11.
A method of treating a subject having cancer comprising administering to the subject a single chain fusion selected from the group comprising amino acid SEQ ID:
- 9, SEQ ID NO:
- 10, and SEQ ID NO:
- 11 and one or more immune checkpoint inhibitors.
42-48. (canceled)
Dependencies are inferred from the claim text.